ArticleExperimental hematology & oncology2017

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL.

Virginie Nägele et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.